Russell Rosenberg, Ph.D, D.ABSM, Founder and CEO of NeuroTrials Research

Russell Rosenberg, PhD

Russell P. Rosenberg, PhD, is currently the chief science officer and CEO of NeuroTrials Research, Inc. and the director of the Atlanta School of Sleep Medicine and Technology in Atlanta, GA. Dr. Rosenberg was the Principle Investigator of the two pivotal Phase III SUNRISE 2 and 1 trials, evaluating Dayvigo (lemborexant) for adults with sleep onset and/or sleep maintenance (insomnia). The U.S. FDA approved Dayvigo in December of 2019 based on the results of the two trials.

Dr. Rosenberg received his Ph.D. in Clinical Research Psychology from Ohio State University and completed a residency in Behavioral Medicine and Sleep Disorders at Rush Presbyterian-St. Luke's Medical Center. His areas of expertise include insomnia and disorders of excessive daytime sleepiness. With over 25 years of experience in clinical sleep medicine and research, Dr. Rosenberg is a Board-Certified Sleep Specialist and Fellow of the American Academy of Sleep Medicine. He served as the Chairman of National Sleep Foundation from July 2011 to August 2013. Dr. Rosenberg is also the founder & director of the Atlanta School of Sleep Medicine, where he lectures and teaches internationally on a range of sleep ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee